Vaxcyte, Inc. (PCVX)
- Previous Close
66.79 - Open
65.00 - Bid 65.52 x 200
- Ask 65.64 x 200
- Day's Range
63.63 - 66.48 - 52 Week Range
44.20 - 82.04 - Volume
919,834 - Avg. Volume
716,433 - Market Cap (intraday)
7.134B - Beta (5Y Monthly) 0.94
- PE Ratio (TTM)
-- - EPS (TTM)
-4.29 - Earnings Date Aug 6, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
103.29
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
vaxcyte.comRecent News: PCVX
Performance Overview: PCVX
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PCVX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PCVX
Valuation Measures
Market Cap
7.13B
Enterprise Value
5.68B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.60
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-436.82M
Diluted EPS (ttm)
-4.29
Balance Sheet and Cash Flow
Total Cash (mrq)
1.08B
Total Debt/Equity (mrq)
2.36%
Levered Free Cash Flow (ttm)
--
Research Analysis: PCVX
Company Insights: PCVX
PCVX does not have Company Insights